HaiPhai serves organizations where expert work, institutional knowledge, governance, and adoption must move together. Biotech is the flagship; the model extends to the life-sciences ecosystem and the capital partners that evaluate and scale it.
Biotech exposes the full AI operating challenge at once: scientific uncertainty, regulated evidence, expert judgment, fragmented knowledge, constrained runway, and consequential decisions. That same operating model applies across CROs, CDMOs, medtech, digital health, private equity, and venture capital; biotech remains the flagship because weak governance and shallow implementation fail there fastest.
Where HaiPhai is deepest. We map AI across the full drug-development value chain — discovery, preclinical, clinical, regulatory, safety, CMC, medical affairs, commercial, and G&A. The bottleneck in clinical-stage biotech is rarely the science; it is the operational load around it.
Knowledge-graph target prioritization across genetics, omics & literature
Trial feasibility simulation & top-enrolling-site identification
Submission-ready module drafting with traceable source linkage
Case intake triage & cross-portfolio signal detection
Batch-record analysis, deviation triage & Module 3 authoring
Launch readiness analytics & market access modeling
The operating model extends to the teams that research, test, manufacture, validate, and deliver regulated health products and services.
The nearest neighbor to our biopharma work. Different artifacts — DHFs, 510(k)s, CERs instead of INDs and CSRs — but the same underlying problem: assembling defensible evidence from scattered sources, under a regulator who expects traceability. The clinical and regulatory muscle transfers directly.
Regulatory · 510(k) predicate analysis & substantial-equivalence argument drafting
Regulatory · Clinical evaluation report (CER) literature synthesis with traceable citations
Quality · Design history file authoring & requirement-to-test traceability
Quality · CAPA drafting & QMS document control copilots
Post-market · Complaint triage & MDR reportability assessment
Validation · Assay and algorithm validation evidence packages
Where clinical workflow meets payer reality. The AI problems here are less about model capability than about operating on protected health information without leaking it — which is the same constraint we design for in trial and lab data. We build inside your VPC and your security posture.
Revenue cycle · Prior-authorization packet assembly & payer documentation automation
Clinical ops · Ambient documentation QA & clinician note review
Population health · Care-gap identification across claims and EHR data
Quality reporting · HEDIS and quality-measure abstraction from unstructured records
Patient-facing · Triage copilots with clinical guardrails and escalation paths
Knowledge · HIPAA-safe retrieval over care protocols and formularies
CROs coordinate scientific judgment, sponsor requirements, sites, vendors, evidence, and timelines across organizational boundaries. The operating opportunity is not generic automation; it is making the study’s decision context traceable while reducing the administrative load surrounding trial delivery.
Study startup · Protocol-to-site packet orchestration and country requirement tracking
Feasibility · Site selection and enrollment scenario synthesis across internal and external evidence
Trial operations · Cross-system issue detection across CTMS, eTMF, EDC, and vendor reporting
Medical writing · CSR, protocol, and briefing-document drafting with source traceability
Quality · TMF completeness review, deviation triage, and CAPA evidence assembly
Business development · RFP response libraries grounded in capabilities, assumptions, and prior solution design
Manufacturing turns scientific intent into controlled, releasable product. CDMOs and life-sciences manufacturers carry a dense operating burden across tech transfer, quality, documentation, supply, and client commitments — exactly where governed knowledge and visible exception handling matter most.
Tech transfer · Process knowledge capture and requirement traceability across sponsor and site teams
Manufacturing · Batch-record review and exception-focused release preparation
Quality · Deviation investigation, root-cause synthesis, and CAPA drafting with evidence links
Validation · Protocol, report, and change-impact package assembly across controlled sources
Supply & capacity · Constraint-aware planning across demand, materials, suites, and campaign schedules
Audit readiness · Inspection evidence retrieval and response coordination across the quality system
Investors face the same collision of fragmented evidence, expert judgment, limited time, and consequential decisions — across both diligence and portfolio operations.
Private equity teams move between high-stakes underwriting and the less tidy reality of portfolio execution. In life sciences and healthcare especially, scientific, regulatory, commercial, and operating evidence must reconcile quickly without flattening uncertainty or obscuring the assumptions behind an investment decision.
Investment diligence · Source-linked investment memo development and red-flag tracking across the data room
Commercial diligence · Market, customer, competitor, and reimbursement evidence synthesis
Operating partners · Portfolio operating diagnostics and evidence-backed 100-day planning
Portfolio intelligence · Comparable KPI normalization, exception detection, and cross-company learning
Value creation · AI opportunity mapping tied to workflow economics, owners, controls, and adoption
Investment committee · Searchable decision memory preserving assumptions, dissent, and follow-up evidence
Venture decisions are made with incomplete evidence, asymmetric expertise, and rapidly changing markets. AI can organize the signal, preserve the reasoning behind conviction, and extend platform support — without pretending that founder judgment or investment judgment can be automated.
Deal flow · Thesis-aware intake, enrichment, and routing without reducing companies to a score
Scientific diligence · Target, modality, translational, clinical, and competitive evidence synthesis
Market intelligence · Living market maps with traceable changes in companies, programs, and financing
Investment committee · Decision briefs that preserve source evidence, assumptions, and open questions
Portfolio monitoring · Milestone, financing, hiring, clinical, and market signal tracking across companies
Platform support · Reusable expert knowledge and founder support workflows across the portfolio
